Us Bancorp \De\ Atea Pharmaceuticals, Inc. Transaction History

Us Bancorp \De\

$74.1 Billion
Q1 2025

A detailed history of Us Bancorp \De\ transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 6,010 shares of AVIR stock, worth $17,789. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,010

Holding current value

$17,789

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$2.9 - $3.52 $17,429 - $21,155	6,010 New	6,010 $17,000
Q1 2024 May 07, 2024	BUY	$3.09 - $4.56 $8,961 - $13,223	2,900 New	2,900 $11,000
Q2 2023 Aug 09, 2023	BUY	$3.21 - $5.06 $3,258 - $5,135	1,015 New	1,015 $3,000
Q4 2022 Feb 13, 2023	SELL	$4.35 - $6.17 $434 - $617	-100 Reduced 27.47%	264 $1,000
Q3 2022 Oct 27, 2022	BUY	$5.49 - $8.79 $1,998 - $3,199	364 New	364 $2,000
Q2 2022 Aug 01, 2022	SELL	$5.33 - $8.18 $1,103 - $1,693	-207 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$5.5 - $9.19 $231 - $385	-42 Reduced 16.87%	207 $1,000
Q4 2021 Feb 11, 2022	BUY	$7.67 - $44.59 $1,549 - $9,007	202 Added 429.79%	249 $2,000
Q3 2021 Nov 10, 2021	BUY	$21.33 - $35.06 $682 - $1,121	32 Added 213.33%	47 $2,000
Q2 2021 Aug 05, 2021	BUY	$19.22 - $59.08 $288 - $886	15 New	15 $0

Others Institutions Holding AVIR

# of Institutions

112

Shares Held

51M

Call Options Held

7.6K

Put Options Held

38.7K

Black Rock Inc. New York, NY

9.12M
Shares

$27 Million
0.0% of portfolio
Bml Capital Management, LLC Zionsville, IN

7.61M
Shares

$22.5 Million
18.41% of portfolio
Tang Capital Management LLC San Diego, CA

4.79M
Shares

$14.2 Million
1.21% of portfolio
Vanguard Group Inc Valley Forge, PA

4.73M
Shares

$14 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

3.34M
Shares

$9.89 Million
0.52% of portfolio

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $246M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account